Ertsey R, Englesberg E
Somat Cell Mol Genet. 1984 Mar;10(2):171-82. doi: 10.1007/BF01534906.
Mutants of Chinese hamster ovary cells (CHO-K1 Pro-), resistant to the proline transport antagonist 2-(methylamino)-isobutyrate (MeAIB) were isolated by a single-step procedure. Mutation rates to Pro+ and to Pro- MeAIB resistance (MeAIBr) are 1.7 X 10(-6) and 2.4 X 10(-5), respectively. Several Pro- MeAIBr mutants were tested by measuring the uptake of 0.05 mM proline through the various amino acid transport systems: some showed increases in one transport system only; others revealed pleiotropic changes affecting two or more systems; still others had no apparent change in proline transport. One Pro- MeAIBr mutant analyzed in detail (MeAIBr22) was isolated after EMS treatment as resistant to 5 mM MeAIB, is Pro-, stable, and shows a 1.6-fold increase in the initial velocity of transport of 0.05 mM proline. There appears to be no change in the velocity of proline transport through the amino acid transport systems A, P, and L, and the "glutamine inhibitable fraction." In contrast, there is a 5.5-fold increase in the velocity of transport of 0.05 mM proline through the ASC system. Kinetic studies reveal a sixfold increase in the Vm and a slight increase in the Km of the transport of serine through the ASC system. Hybrids between MeAIBr22 and CHO-K1 Pro-, OUAr, HPRT- showed the parental phenotype. These results indicate that the mutant ASC phenotype of MeAIBr22 is recessive and is probably the result of a regulatory gene mutation.
通过一步法分离出对脯氨酸转运拮抗剂2-(甲氨基)异丁酸(MeAIB)具有抗性的中国仓鼠卵巢细胞(CHO-K1 Pro-)突变体。对Pro+和对Pro- MeAIB抗性(MeAIBr)的突变率分别为1.7×10^(-6)和2.4×10^(-5)。通过测量0.05 mM脯氨酸通过各种氨基酸转运系统的摄取量,对几个Pro- MeAIBr突变体进行了测试:一些突变体仅在一种转运系统中表现出增加;其他突变体则表现出影响两个或更多系统的多效性变化;还有一些突变体在脯氨酸转运方面没有明显变化。详细分析的一个Pro- MeAIBr突变体(MeAIBr22)是在EMS处理后分离得到的,对5 mM MeAIB具有抗性,是Pro-型,稳定,并且在0.05 mM脯氨酸转运的初始速度上增加了1.6倍。通过氨基酸转运系统A、P和L以及“谷氨酰胺可抑制部分”的脯氨酸转运速度似乎没有变化。相比之下,通过ASC系统的0.05 mM脯氨酸转运速度增加了5.5倍。动力学研究表明,通过ASC系统的丝氨酸转运的Vm增加了六倍,Km略有增加。MeAIBr22与CHO-K1 Pro-、OUAr、HPRT-之间的杂种表现出亲本表型。这些结果表明,MeAIBr22的突变ASC表型是隐性的,可能是调节基因突变的结果。